Advertisement

Ovarielles Überstimulationssyndrom

  • Alexandra Petra BielfeldEmail author
  • Jan-Steffen Krüssel
  • Dunja-Maria Baston-Büst
Living reference work entry
Part of the Springer Reference Medizin book series (SRM)

Zusammenfassung

Das ovarielle Überstimulationssyndrom bleibt bis heute ein Risiko in der Kinderwunschtherapie, kann aber in seltenen Fällen auch spontan auftreten. Es gilt für die Praxis, Patientinnen mit erhöhtem Risiko vor Beginn einer Stimulationsbehandlung zu identifizieren (z. B. Patientinnen mit PCOS, hohem AMH-Wert, großer Anzahl antraler Follikel). Innerhalb der Stimulationstherapie können weitere Risikofaktoren identifiziert werden, z. B. hohe Östradiolwerte, >10 Follikel >13 mm. Bei Einsatz des mittlerweile in Deutschland hauptsächlich angewandten Antagonistenprotokolls besteht die Möglichkeit, die finale Oozytenmaturation mittels GnRH-Agonist zu triggern und einen Embryotransfer auf einen unstimulierten Zyklus zu verschieben, denn hCG gilt als ultimativer Trigger eines OHSS insbesondere auch beim Eintritt einer Schwangerschaft in einem hoch stimulierten Zyklus. Die für die Stimulation gewählte Dosis sollte daher abhängig von den Charakteristika der Patientin individuell angepasst werden.

Literatur

  1. Abdallah R, Kligman I, Davis O, Rosenwaks Z (2010) Withholding gonadotropins until human chorionic gonadotropin administration. Semin Reprod Med 28:486–492CrossRefGoogle Scholar
  2. Al-Ramahi M, Leader A, Claman P, Spence J (1997) A novel approach to the treatment of ascites associated with ovarian hyperstimulation syndrome. Hum Reprod 12:2614–2616CrossRefGoogle Scholar
  3. Álvarez C, Alonso-Muriel I, García G, Crespo J, Bellver J, Simón C, Pellicer A (2007a) Implantation is apparently unaffected by the dopamine agonist Cabergoline when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment: a pilot study. Hum Reprod 22:3210–3214.  https://doi.org/10.1093/humrep/dem315CrossRefPubMedGoogle Scholar
  4. Álvarez C, Martí-Bonmatí L, Novella-Maestre E, Sanz R, Gómez R, FernÁndez-SÁnchez M, Simón C, Pellicer A (2007b) Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. J Clin Endocrinol Metab 92:2931–2937.  https://doi.org/10.1210/jc.2007-0409CrossRefPubMedGoogle Scholar
  5. Artini PG, Monti M, Fasciani A, Battaglia C, D’Ambrogio G, Genazzani AR (2002) Vascular endothelial growth factor, interleukin-6 and interleukin-2 in serum and follicular fluid of patients with ovarian hyperstimulation syndrome. Eur J Obstet Gynecol Reprod Biol 101:169–174. http://www.sciencedirect.com/science/article/pii/S0301211501005681CrossRefGoogle Scholar
  6. Atkinson P, Koch J, Ledger W (2014) GnRH agonist trigger and a freeze-all strategy to prevent ovarian hyperstimulation syndrome: a retrospective study of OHSS risk and pregnancy rates. Aust N Z J Obstet Gynaecol 54:581–585CrossRefGoogle Scholar
  7. Binder H, Griesinger G, Kiesel L (2007) Ovarielles Überstimulationssyndrom. Gynäkologische Endokrinol 5:203–211CrossRefGoogle Scholar
  8. Binder H, Flegel W, Emran J, Müller A, Cupisti S, Beckmann M, Eckstein R, Dittrich R, Ringwald J (2008) Blood group A: an overseen risk factor for early-onset ovarian hyperstimulation syndrome? Reprod Biomed Online 17:185–189CrossRefGoogle Scholar
  9. Bonilla-Musoles F, Raga F, Castillo J, Sanz M, Dolz M, Osborne N (2009) High doses of GnRH antagonists are efficient in the management of severe ovarian hyperstimulation syndrome. Clin Exp Obstet Gynecol 36:78–81PubMedGoogle Scholar
  10. Brinsden P, Wada I, Tan S, Balen A, Jacobs H (1995) Diagnosis, prevention and management of ovarian hyperstimulation syndrome. BJOG 102:767–772CrossRefGoogle Scholar
  11. Budev M, Arroliga A, Falcone T (2005) Ovarian hyperstimulation syndrome. Crit Care Med 33:S301–S306CrossRefGoogle Scholar
  12. Cerrillo M, Rodríguez S, Mayoral M, Pacheco A, Martínez-Salazar J, Garcia-Velasco JA (2009) Differential regulation of VEGF after final oocyte maturation with GnRH agonist versus hCG: a rationale for OHSS reduction. Fertil Steril 91:1526–1528. http://www.sciencedirect.com/science/article/pii/S0015028208038284CrossRefGoogle Scholar
  13. Chauhan AR, Prasad M, Chamariya S, Achrekar S, Mahale SD, Mittal K (2015) Novel FSH receptor mutation in a case of spontaneous ovarian hyperstimulation syndrome with successful pregnancy outcome. J Hum Reprod Sci 8:230–233. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4691976/CrossRefGoogle Scholar
  14. Chen S-U, Chou C-H, Lin C-W, Lee H, Wu J-C, Lu H-F, Chen C-D, Yang Y-S (2010) Signal mechanisms of vascular endothelial growth factor and interleukin-8 in ovarian hyperstimulation syndrome: dopamine targets their common pathways. Hum Reprod 25:757–767.  https://doi.org/10.1093/humrep/dep432CrossRefPubMedGoogle Scholar
  15. Corbett S, Shmorgun D, Claman P (2014) The prevention of ovarian hyperstimulation syndrome. J Obstet Gynaecol Can 36:1024–1033. http://www.sciencedirect.com/science/article/pii/S1701216315304175CrossRefGoogle Scholar
  16. De Leener A, Montanelli L, Van Durme J, Chae H, Smits G, Vassart G, Costagliola S (2006) Presence and absence of follicle-stimulating hormone receptor mutations provide some insights into spontaneous ovarian hyperstimulation syndrome physiopathology. J Clin Endocrinol Metab 91:555–562.  https://doi.org/10.1210/jc.2005-1580CrossRefPubMedGoogle Scholar
  17. Delbaere A, Bergmann PJM, Gervy-Decoster C, Staroukine M, Englert Y (1994) Angiotensin II immunoreactivity is elevated in ascites during severe ovarian hyperstimulation syndrome: implications for pathophysiology and clinical management**Supported by grant 1.5.218.94F from the Fonds National de la Recherche Scientifique (F.N.R.S.). Fertil Steril 62:731–737. http://www.sciencedirect.com/science/article/pii/S0015028216569970CrossRefGoogle Scholar
  18. Elchalal U, Schenker J (1997) The pathophysiology of ovarian hyperstimulation syndrome – views and ideas. Hum Reprod 12:1129–1137CrossRefGoogle Scholar
  19. Enskog A, Nilsson L, Brännström M (2000) Peripheral blood concentrations of inhibin B are elevated during gonadotrophin stimulation in patients who later develop ovarian OHSS and inhibin A concentrations are elevated after OHSS onset. Hum Reprod 15:532–538CrossRefGoogle Scholar
  20. Forman RG, Frydman R, Egan D, Ross C, Barlow DH (1990) Severe ovarian hyperstimulation syndrome using agonists of gonadotropin-releasing hormone for in vitro fertilization: a European series and a proposal for prevention**Presented in part at the 6th World Congress on In Vitro Fertilization, Jerusalem, Israel. Fertil Steril 53:502–509. http://www.sciencedirect.com/science/article/pii/S0015028216533482CrossRefGoogle Scholar
  21. Gao M-Z, Zhao X-M, Sun Z-G, Hong Y, Zhao L-W, Zhang H-Q (2011) Endocrine gland-derived vascular endothelial growth factor concentrations in follicular fluid and serum may predict ovarian hyperstimulation syndrome in women undergoing controlled ovarian hyperstimulation. Fertil Steril 95:673–678. http://www.sciencedirect.com/science/article/pii/S0015028210026063CrossRefGoogle Scholar
  22. Geva E, Lessing JB, Lerner-Geva L, Azem F, Yovel I, Amit A (1997) Elevated levels of interleukin-6 in the follicular fluid at the time of oocyte retrieval for in vitro fertilization may predict the development of early-form ovarian hyperstimulation syndrome. Fertil Steril 68:133–137. http://www.sciencedirect.com/science/article/pii/S0015028297814896CrossRefGoogle Scholar
  23. Golan A, Ron-el R, Herman A, Soffer Y, Weinraub Z, Caspi E (1989) Ovarian hyperstimulation syndrome: an update review. Obstet Gynecol Surv 44:430–440CrossRefGoogle Scholar
  24. Griesinger G, Diedrich K, Tarlatzis B, Kolibianakis E (2006) GnRH-antagonists in ovarian stimulation for IVF in patients with poor response to gonadotrophins, polycystic ovary syndrome, and risk of ovarian hyperstimulation: a meta-analysis. Reprod Biomed Online 13:628–638CrossRefGoogle Scholar
  25. Griesinger G, Binder H, Diedrich K (2008) Neue Ansätze bei der Prävention des ovariellen Überstimulationssyndroms. Gynäkologische Endokrinol 6:165–170CrossRefGoogle Scholar
  26. Griesinger G, Schultz L, Bauer T, Broessner A, Frambach T, Kissler S (2011) Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing hormone antagonist protocol in combination with a „freeze-all“ strategy: a prospective multicentric study. Fertil Steril 95:2029–2033.e1. http://www.sciencedirect.com/science/article/pii/S0015028211002421CrossRefGoogle Scholar
  27. Haas J, Baum M, Meridor K, Hershko-Klement A, Elizur S, Hourvitz A, Orvieto R, Yinon Y (2018) Is severe OHSS associated with adverse pregnancy outcomes? Evidence from a case-control study. Reprod Biomed Online 29:216–221.  https://doi.org/10.1016/j.rbmo.2014.04.015CrossRefGoogle Scholar
  28. Kerkelä E, Skottman H, Friden B, Bjuresten K, Kere J, Hovatta O (2007) Exclusion of coding-region mutations in luteinizing hormone and follicle-stimulating hormone receptor genes as the cause of ovarian hyperstimulation syndrome. Fertil Steril 87:603–606.  https://doi.org/10.1016/j.fertnstert.2006.06.060CrossRefPubMedGoogle Scholar
  29. Kissler S, Neidhardt B, Siebzehnrübl E, Schmitt H, Tschaikowsky K, Wildt L (2001) The detrimental role of colloidal volume substitutes in severe ovarian hyperstimulation syndrome: a case report. Eur J Obstet Gynecol Reprod Biol 99:131–134. http://www.sciencedirect.com/science/article/pii/S0301211501003645CrossRefGoogle Scholar
  30. Kolibianakis EM, Collins J, Tarlatzis BC, Devroey P, Diedrich K, Griesinger G (2006) Among patients treated for IVF with gonadotrophins and GnRH analogues, is the probability of live birth dependent on the type of analogue used? A systematic review and meta-analysis. Hum Reprod Update 12:651–671.  https://doi.org/10.1093/humupd/dml038CrossRefPubMedGoogle Scholar
  31. Kolibianakis EM, Papanikolaou EG, Tournaye H, Camus M, Van Steirteghem AC, Devroey P (2007) Triggering final oocyte maturation using different doses of human chorionic gonadotropin: a randomized pilot study in patients with polycystic ovary syndrome treated with gonadotropin-releasing hormone antagonists and recombinant follicle-stimulating horm. Fertil Steril 88:1382–1388. http://www.sciencedirect.com/science/article/pii/S0015028207001100CrossRefGoogle Scholar
  32. Kosaka K, Fujiwara H, Yoshioka S, Fujii S (2007) Vascular endothelial growth factor production by circulating immune cells is elevated in ovarian hyperstimulation syndrome. Hum Reprod 22:1647–1651.  https://doi.org/10.1093/humrep/dem042CrossRefPubMedGoogle Scholar
  33. Lainas GT, Kolibianakis EM, Sfontouris IA, Zorzovilis IZ, Petsas GK, Lainas TG, Tarlatzis BC (2013) Pregnancy and neonatal outcomes following luteal GnRH antagonist administration in patients with severe early OHSS. Hum Reprod 28:1929–1942.  https://doi.org/10.1093/humrep/det114CrossRefPubMedGoogle Scholar
  34. Luke B, Brown MB, Morbeck DE, Hudson SB, Coddington CC III, Stern JE (2018) Factors associated with ovarian hyperstimulation syndrome (OHSS) and its effect on assisted reproductive technology (ART) treatment and outcome. Fertil Steril 94:1399–1404.  https://doi.org/10.1016/j.fertnstert.2009.05.092CrossRefGoogle Scholar
  35. Manau D, Fábregues F, Arroyo V, Jiménez W, Vanrell JA, Balasch J (2002) Hemodynamic changes induced by urinary human chorionic gonadotropin and recombinant luteinizing hormone used for inducing final follicular maturation and luteinization. Fertil Steril 78:1261–1267. http://www.sciencedirect.com/science/article/pii/S0015028202043947CrossRefGoogle Scholar
  36. McClure N, Leya J, Radwanska E, Rawlins R, Haning RJ (2000) Luteal phase support and severe ovarian hyperstimulation syndrome. Hum Reprod 7:758–764CrossRefGoogle Scholar
  37. McElhinney B, Ardill J, Caldwell C, Lloyd F, McClure N (2002) Ovarian hyperstimulation syndrome and assisted reproductive technologies: why some and not others? Hum Reprod 17:1548–1553CrossRefGoogle Scholar
  38. Mensah J, Kimmig R, Schmidt M (2010) Ovarielles Überstimulationssyndrom in einer aneuploiden Gravidität. Geburtshilfe Frauenheilkd 70:828–831CrossRefGoogle Scholar
  39. Morris R, Paulson R (1994) Ovarian derived prorenin-angiotensin cascade in human reproduction. Fertil Steril1 62:1105–1114CrossRefGoogle Scholar
  40. Muller P (1962) In: Beclere C (Hrsg) Gonadotrophines en Gynecologie, Bd 137. Masson, ParisGoogle Scholar
  41. Nargund G, Hutchison L, Scaramuzzi R, Campbell S (2007) Low-dose HCG is useful in preventing OHSS in high-risk women without adversely affecting the outcome of IVF cycles. Reprod Biomed Online 14:682–685CrossRefGoogle Scholar
  42. Navot D, Bergh P, Laufer N (1992) Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertil Steril 58:249–261CrossRefGoogle Scholar
  43. Neulen J, Yan Z, Raczek S, Weindel K, Keck C, Weich HA, Marmé D, Breckwoldt M (1995) Human chorionic gonadotropin-dependent expression of vascular endothelial growth factor/vascular permeability factor in human granulosa cells: importance in ovarian hyperstimulation syndrome. J Clin Endocrinol Metab 80:1967–1971.  https://doi.org/10.1210/jcem.80.6.7775647CrossRefPubMedGoogle Scholar
  44. Nyboe Andersen A, Nelson SM, Fauser BCJM, García-Velasco JA, Klein BM, Arce J-C (2017) Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial. Fertil Steril 107:387–396.e4. http://www.sciencedirect.com/science/article/pii/S0015028216629564CrossRefGoogle Scholar
  45. Olivennes F (2010) Ovarian hyperstimulation syndrome prevention strategies: individualizing gonadotropin dose. Semin Reprod Med 28:463–467CrossRefGoogle Scholar
  46. Orvieto R, Dekel A, Dicker D, Bar-Hava I, Ben-Rafael Z (1995) A severe case of ovarian hyperstimulation syndrome despite the prophylactic administration of intravenous albumin. Fertil Steril 64:860–862. http://www.sciencedirect.com/science/article/pii/S0015028216578674CrossRefGoogle Scholar
  47. Papanikolaou EG, Tournaye H, Verpoest W, Camus M, Vernaeve V, Van Steirteghem A, Devroey P (2005) Early and late ovarian hyperstimulation syndrome: early pregnancy outcome and profile. Hum Reprod 20:636–641.  https://doi.org/10.1093/humrep/deh638CrossRefPubMedGoogle Scholar
  48. Pellicer A, Albert C, Mercader A, Bonilla-Musoles F, Remohí J, Simón C (1999) The pathogenesis of ovarian hyperstimulation syndrome: in vivo studies investigating the role of interleukin-1β, interleukin-6, and vascular endothelial growth factor. Fertil Steril 71:482–489. http://www.sciencedirect.com/science/article/pii/S0015028298004841CrossRefGoogle Scholar
  49. Raziel A, Friedler S, Schachter M, Strassburger D, Mordechai E, Ron-El R (2002) Increased early pregnancy loss in IVF patients with severe ovarian hyperstimulation syndrome. Hum Reprod 17:107–110CrossRefGoogle Scholar
  50. Rizk B (2009) Symposium: update on prediction and management of OHSS. Genetics of ovarian hyperstimulation syndrome. Reprod Biomed Online 19:14–27CrossRefGoogle Scholar
  51. Rizk B, Aboulghar M (1999) Classification, pathophysiology and management of ovarian hyperstimulation syndrome. In: Brinsden P et al (Hrsg) A textbook of invitro fertilisation, 2. Aufl. Lancanster, UK, Parthenon Publishing, S 131–155Google Scholar
  52. Rollene NL, Amols MH, Hudson SBA, Coddington CC (2009) Treatment of ovarian hyperstimulation syndrome using a dopamine agonist and gonadotropin releasing hormone antagonist: a case series. Fertil Steril 92:1169.e15–1169.e17. http://www.sciencedirect.com/science/article/pii/S0015028209012102CrossRefGoogle Scholar
  53. Shapiro A, Thomas T, Epstein M (1977) Management of hyperstimulation syndrome. Fertil Steril 28:237–239CrossRefGoogle Scholar
  54. Steward RG, Lan L, Shah AA, Yeh JS, Price TM, Goldfarb JM, Muasher SJ (2014) Oocyte number as a predictor for ovarian hyperstimulation syndrome and live birth: an analysis of 256,381 in vitro fertilization cycles. Fertil Steril 101:967–973. http://www.sciencedirect.com/science/article/pii/S0015028213034584CrossRefGoogle Scholar
  55. Tan SL, Child TJ, Cheung AP, Fluker MR, Yuzpe A, Casper R, Leung P, Cadesky K, Davis VJ (2005) A randomized, double-blind, multicenter study comparing a starting dose of 100 IU or 200 IU of recombinant follicle stimulating hormone (Puregon®) in women undergoing controlled ovarian hyperstimulation for IVF treatment. J Assist Reprod Genet 22:81–88. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3455475/CrossRefGoogle Scholar
  56. The European Recombinant LH Study Group (2001) Human recombinant luteinizing hormone is as effective as, but safer than, urinary human chorionic gonadotropin in inducing final follicular maturation and ovulation in in vitro fertilization procedures: results of a multicenter double-blind study. J Clin Endocrinol Metab 86:2607–2618.  https://doi.org/10.1210/jcem.86.6.7599CrossRefGoogle Scholar
  57. Uchida S, Uchida H, Maruyama T, Kajitani T, Oda H, Miyazaki K, Kagami M, Yoshimura Y (2013) Molecular analysis of a mutated FSH receptor detected in a patient with spontaneous ovarian hyperstimulation syndrome (Luque RM, Hrsg). PLoS One 8:e75478. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3772932/CrossRefGoogle Scholar
  58. Verit FF, Cetin O, Yildirim O, Keskin S, Yucel O, Yalcinkaya S (2014) Neutrophil to lymphocyte ratio is superior to platelet to lymphocyte ratio as an early predictor of moderate/severe ovarian hyperstimulation syndrome. J Obstet Gynaecol (Lahore) 34:639–643.  https://doi.org/10.3109/01443615.2014.920792CrossRefGoogle Scholar
  59. Wang T-H, Horng S-G, Chang C-L, Wu H-M, Tsai Y-J, Wang H-S, Soong Y-K (2002) Human chorionic gonadotropin-induced ovarian hyperstimulation syndrome is associated with up-regulation of vascular endothelial growth factor. J Clin Endocrinol Metab 87:3300–3308.  https://doi.org/10.1210/jcem.87.7.8651CrossRefPubMedGoogle Scholar
  60. Zalel Y, Katz Z, Caspi B, Ben-Hur H, Dgani R, Insler V (1992) Spontaneous ovarian hyperstimulation syndrome concomitant with spontaneous pregnancy in a woman with polycystic ovary disease. Am J Obstet Gynecol 167:122–124.  https://doi.org/10.1016/S0002-9378(11)91642-1CrossRefPubMedGoogle Scholar
  61. Zivi E, Simon A, Laufer N (2010) Ovarian hyperstimulation syndrome: definition, incidience, and classification. Semin Reprod Med 28:441–447CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature 2019

Authors and Affiliations

  • Alexandra Petra Bielfeld
    • 1
    Email author
  • Jan-Steffen Krüssel
    • 1
  • Dunja-Maria Baston-Büst
    • 1
  1. 1.Universitäres interdisziplinäres Kinderwunschzentrum DüsseldorfDüsseldorfDeutschland

Personalised recommendations